Immunome Stock - analyst focus after Morphimmune merger

Immunome stock draws renewed analyst attention following the recent completion of its merger with Morphimmune and a shift toward oncology and radiopharmaceutical partnerships. This Friday, the focus is on how the company now fits into its competitive biotech peer group.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 16:43 CET. Details in the imprint.

Immunome (US45254C1062) has been repositioning itself in oncology drug development following its merger with Morphimmune late last year. The combined company now attracts closer comparison with a broader set of clinical-stage biotech peers, particularly those active in targeted cancer therapeutics.

How Immunome reached this point

Immunome completed its merger with Morphimmune in the fourth quarter of 2023, creating a combined platform focused on targeted cancer therapies and leveraging Morphimmune’s precision oncology assets alongside Immunome’s antibody discovery capabilities, according to company disclosures on its investor site. The Immunome investor relations materials describe a broadened pipeline following the transaction.

The company has emphasized oncology and radiopharmaceutical programs as central to its post-merger strategy. Management communications highlight efforts to integrate discovery platforms and rationalize overlapping projects to concentrate resources on the most promising clinical candidates.

Friday focus on sector and peers

This Friday, the lens is on Immunome’s positioning relative to other clinical-stage oncology developers listed on Nasdaq. The stock now competes for attention with peers engaged in antibody-drug conjugates, radiopharmaceuticals and other targeted oncology approaches, many of which remain years from potential commercialization.

In this peer group, investors typically compare pipeline breadth, partnership potential and cash runways. Companies without approved products are often evaluated on the quality of their clinical data, licensing deals with larger pharma groups and the clarity of their development timelines rather than near-term earnings metrics.

What the company works on

Immunome’s core business centers on discovering and developing antibody-based therapies and related oncology candidates that target novel or under-explored antigens in cancer. The company aims to build a pipeline of differentiated drug candidates, including assets that may be advanced alone or in collaboration with larger pharmaceutical partners.

Where the stock trades today

The shares of Immunome trade on Nasdaq in US dollars; a precise, real-time quote was not reliably verifiable at the time of this editorial review.

Key facts on Immunome stock

• Company: Immunome Inc.
• ISIN: US45254C1062
• Ticker: IMNM
• Venue: Nasdaq

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.